A bill to amend title XVIII of the Social Security Act to require drug manufacturers to provide rebates for drugs furnished under Medicare part B for which the growth in average sales price has exceeded inflation, and for other purposes.
About This Bill
Committee
Latest Action · July 10, 2019
Read twice and referred to the Committee on Finance.
Stop Drug Companies from Overcharging Seniors in Medicare Part B Act of 2019
This bill requires manufacturers of covered drugs under Medicare medical services to issue rebates to the Centers for Medicare & Medicaid Services. Rebates are calculated based on the number of units sold and the amount by which the manufacturer price exceeds inflation. The bill's requirements do not apply to drugs that cost less than $100 annually per user in 2020 (and as adjusted for inflation annually thereafter) or to drugs on a specified drug shortage list.
The bill also eliminates cost-sharing for such drugs for beneficiaries whose out-of-pocket costs meet or exceed a specified threshold.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.